Heart failure / obesità

Synthetic apelin mimetics for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 28, 2013, is named PAT054961-US-NP_SL.txt and is 67,220 bytes in size. FIELD OF THE

Synthetic apelin mimetics for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 28, 2013, is named PAT054961-US-NP_SL.txt and is 67,220 bytes in size. FIELD OF THE

Synthetic apelin mimetics for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 28, 2013, is named PAT054961-US-NP_SL.txt and is 67,220 bytes in size. FIELD OF THE

Disulfide cyclic polypeptides for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The invention relates to novel compositions comprising modified peptide and polypeptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than

Synthetic linear apelin mimetics for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The invention relates to novel compositions comprising modified peptide and polypeptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than

Cyclic polypeptides for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The invention relates to novel compositions comprising modified peptide and polypeptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than

Cyclic polypeptides for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 29, 2014, is named PAT055418-US-NP_SL.txt and is 44,387 bytes in size. FIELD OF THE

Cyclic apelin derivatives for the treatment of heart failure

Solo gli utenti registrati possono tradurre articoli

Entra registrati

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 29, 2014, is named PAT055656_SL.txt and is 14,498 bytes in size. FIELD OF THE

Compounds and methods for treating insulin resistance and cardiomyopathy

Solo gli utenti registrati possono tradurre articoli

Entra registrati

BACKGROUND All publications mentioned herein are cited for the purpose of familiarizing the reader with the background of the invention. Nothing herein is to be construed as an admission that these references are prior art in relation to the inventions described herein. Although Type 2 Diabetes

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The present invention is directed to tetrahydroisoquinoline derivative compounds which inhibit diacylglyceride O-acyltransferase 2 ("DGAT2"), and their use for preventing, treating or acting as a remedial agent for hepatic steatosis, type-2 diabetic mellitus, obesity,

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Solo gli utenti registrati possono tradurre articoli

Entra registrati

FIELD OF THE INVENTION The present invention is directed to tetrahydroisoquinoline derivative compounds which inhibit diacylglyceride O-acyltransferase 2 ("DGAT2"), and their use for preventing, treating or acting as a remedial agent for hepatic steatosis, type-2 diabetic mellitus, obesity,

Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands

Solo gli utenti registrati possono tradurre articoli

Entra registrati

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to certain substituted benzylamine derivatives which selectively bind to mammalian Neuropeptide Y1 (NPY1) receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates

Organic compounds

Solo gli utenti registrati possono tradurre articoli

Entra registrati

This application is the National Stage of Application No. PCT/US07/64974 filed Mar. 27, 2007, which claims benefit under 35 U.S.C. .sctn.119(e) of U.S. Provisional Application No. 60/787,104, filed Mar. 29, 2006, the contents of which are incorporated herein by reference in their entirety. The

Pyrazolopyridine compound and processes for preparation thereof

Solo gli utenti registrati possono tradurre articoli

Entra registrati

The present invention relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof. More particularly, it relates to novel pyrazolopyridine compound and a pharmaceutically acceptable salt thereof, which are adenosine antagonists and possess various pharmaceutical actions

Certain substituted benzylamine derivatives a new class of neuropeptide Y1 specific ligands

Solo gli utenti registrati possono tradurre articoli

Entra registrati

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to certain substituted benzylamine derivatives which selectively bind to mammalian Neuropeptide Y1 (NPY1) receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates

heart failure/obesità

Synthetic apelin mimetics for the treatment of heart failure

Synthetic apelin mimetics for the treatment of heart failure

Synthetic apelin mimetics for the treatment of heart failure

Disulfide cyclic polypeptides for the treatment of heart failure

Synthetic linear apelin mimetics for the treatment of heart failure

Cyclic polypeptides for the treatment of heart failure

Cyclic polypeptides for the treatment of heart failure

Cyclic apelin derivatives for the treatment of heart failure

Compounds and methods for treating insulin resistance and cardiomyopathy

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands

Organic compounds

Pyrazolopyridine compound and processes for preparation thereof

Certain substituted benzylamine derivatives a new class of neuropeptide Y1 specific ligands

Il database di erbe medicinali più completo supportato dalla scienza